Evolocumab Comparison in Healthy Subjects

This trial tests two versions of a drug called evolocumab to observe how the body processes them. Evolocumab helps manage cholesterol levels. Researchers aim to understand how each version works in healthy individuals. The trial seeks adults with a BMI between 18 and 32 and a specific range of LDL cholesterol levels. As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, offering participants an opportunity to contribute to groundbreaking medical research.

Research has shown that evolocumab is generally safe for people. Studies have found that common side effects, such as a sore throat or a cold, occur in about 6.5% of patients and are mild. Serious issues are rare. The FDA has approved evolocumab to help lower bad cholesterol (LDL) for those needing more assistance than standard treatments provide. Long-term studies in animals did not find any cancer-related problems with evolocumab. Overall, evolocumab appears safe for people when used as directed by healthcare providers.¹²³⁴⁵

Researchers are excited about evolocumab because it offers a novel approach to managing high cholesterol levels. Unlike traditional statins, which reduce cholesterol by blocking its production in the liver, evolocumab is a monoclonal antibody that targets and inhibits a protein called PCSK9. This results in more LDL receptors being available to clear LDL cholesterol from the bloodstream, potentially leading to a more significant reduction in LDL cholesterol levels. Evolocumab is administered as a subcutaneous injection, which may be more convenient for some patients compared to daily oral medications. This unique mechanism and delivery method could provide a powerful option for those who don’t respond well to or cannot tolerate statins.

This trial will compare two formulations of evolocumab: Drug Substance A (Test) and Drug Substance B (Reference). Studies have shown that evolocumab effectively lowers LDL cholesterol, often called "bad" cholesterol, reducing LDL levels by about 60% in people with high cholesterol. Research also shows that evolocumab can lower the risk of heart problems, such as heart attacks, especially when combined with other cholesterol-lowering treatments. Previous findings have demonstrated the drug's safety and effectiveness over long periods, consistently reducing heart-related risks. These results suggest evolocumab could be a strong option for managing cholesterol-related health issues.⁶⁷⁸⁹¹⁰